Topotecan acetate | CAS#123948-88-9 | topoisomerase inhibitor

MedKoo Cat#: 414450 | Name: Topotecan acetate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Topotecan is a topoisomerase inhibitor. It is a synthetic, water-soluble analog of the natural chemical compound camptothecin. In physiological environments, topotecan is in equilibrium with its inactive carboxylate form. Topotecan's active lactone form intercalates between DNA bases in the topoisomerase-I cleavage complex. The binding of topotecan in the cleavage complex prevents topoisomerase-I from religating the nicked DNA strand after relieving the strain. This intercalation therefore traps the topoisomerase-I in the cleavage complex bound to the DNA. When the replication-fork collides with the trapped topoisomerase-I, DNA damage occurs. This disruption prevents DNA replication and ultimately leads to cell death.

Chemical Structure

Topotecan acetate

CAS#123948-88-9 (acetate)

Theoretical Analysis

MedKoo Cat#: 414450

Name: Topotecan acetate

CAS#: 123948-88-9 (acetate)

Chemical Formula: C25H27N3O7

Exact Mass: 421.1638

Molecular Weight: 481.51

Elemental Analysis: C, 62.36; H, 5.65; N, 8.73; O, 23.26

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 450.00	2 Weeks
100mg	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

123948-88-9 (acetate) 123948-87-8 (free base) 119413-54-6 (HCl)

Synonym

Topotecan acetate; NSC 609699 NSC-609699 NSC609699; SKF S104864A. SKF 104864 A SKF-104864-A; SKF104864A; TOPO. Hycamtamine; Nogitecan; Topotecan; Topocecan free base

IUPAC/Chemical Name

1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-, (S)-, acetic acid

InChi Key

LYUVKGDSGUQAAH-BQAIUKQQSA-N

InChi Code

InChI=1S/C23H23N3O5.C2H4O2/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20;1-2(3)4/h5-8,27,30H,4,9-11H2,1-3H3;1H3,(H,3,4)/t23-;/m0./s1

SMILES Code

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O.CC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 481.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Alshammari MK, Alghazwni MK, Alharbi AS, Alqurashi GG, Kamal M, Alnufaie SR, Alshammari SS, Alshehri BA, Tayeb RH, Bougeis RJM, Aljehani AA, Alotaibi NM, Abida A, Imran M. Nanoplatform for the Delivery of Topotecan in the Cancer Milieu: An Appraisal of its Therapeutic Efficacy. Cancers (Basel). 2022 Dec 22;15(1):65. doi: 10.3390/cancers15010065. PMID: 36612067; PMCID: PMC9817931. 2: Mills H, Acquah R, Tang N, Cheung L, Klenk S, Glassen R, Pirson M, Albert A, Hoang DT, Van TN. A Critical Scrutiny on Liposomal Nanoparticles Drug Carriers as Modelled by Topotecan Encapsulation and Release in Treating Cancer. Evid Based Complement Alternat Med. 2022 Aug 9;2022:7702512. doi: 10.1155/2022/7702512. Retraction in: Evid Based Complement Alternat Med. 2023 Dec 13;2023:9816492. doi: 10.1155/2023/9816492. PMID: 35983007; PMCID: PMC9381203. 3: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Topotecan. 2021 Aug 16. PMID: 30372006. 4: Upadhyayula PS, Spinazzi EF, Argenziano MG, Canoll P, Bruce JN. Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience. Pharmaceutics. 2020 Dec 30;13(1):39. doi: 10.3390/pharmaceutics13010039. PMID: 33396668; PMCID: PMC7823846. 5: Rosen VM, Guerra I, McCormack M, Nogueira-Rodrigues A, Sasse A, Munk VC, Shang A. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First- Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab- Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer. Int J Gynecol Cancer. 2017 Jul;27(6):1237-1246. doi: 10.1097/IGC.0000000000001000. PMID: 28448304; PMCID: PMC5499964. 6: Saraf S, Jain A, Hurkat P, Jain SK. Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform. Crit Rev Ther Drug Carrier Syst. 2016;33(5):401-432. doi: 10.1615/CritRevTherDrugCarrierSyst.2016015926. PMID: 27910741. 7: Bracher F, Tremmel T. From Lead to Drug Utilizing a Mannich Reaction: The Topotecan Story. Arch Pharm (Weinheim). 2017 Jul;350(7). doi: 10.1002/ardp.201600236. Epub 2016 Nov 2. PMID: 27805723. 8: Rao V, Bauer F, Vredenburgh JJ. Refractory Small Cell Carcinoma of the Ovary - Hypercalcemic Type (SCCOHT) Treated with Romidepsin and Topotecan: A Case Report and Review of the Literature. Conn Med. 2016 Oct;80(9):529-532. PMID: 29772136. 9: Vennepureddy A, Atallah JP, Terjanian T. Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature. World J Oncol. 2015 Oct;6(5):429-436. doi: 10.14740/wjon950e. Epub 2015 Oct 26. PMID: 28983343; PMCID: PMC5624667. 10: Francis JH, Marr BP, Schaiquevich P, Kellick MG, Abramson DH. Properties and clinical utility of topotecan fluorescence: uses for retinoblastoma. Br J Ophthalmol. 2015 Oct;99(10):1320-2. doi: 10.1136/bjophthalmol-2015-306633. Epub 2015 Apr 29. PMID: 25926516. 11: Edwards SJ, Barton S, Thurgar E, Trevor N. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health Technol Assess. 2015 Jan;19(7):1-480. doi: 10.3310/hta19070. PMID: 25626481; PMCID: PMC4781035. 12: Schaiquevich P, Carcaboso AM, Buitrago E, Taich P, Opezzo J, Bramuglia G, Chantada GL. Ocular pharmacology of topotecan and its activity in retinoblastoma. Retina. 2014 Sep;34(9):1719-27. doi: 10.1097/IAE.0000000000000253. PMID: 25099219. 13: Musa F, Blank S, Muggia F. A pharmacokinetic evaluation of topotecan as a cervical cancer therapy. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):215-24. doi: 10.1517/17425255.2013.758249. PMID: 23320990. 14: Riemsma R, Simons JP, Bashir Z, Gooch CL, Kleijnen J. Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer. 2010 Aug 17;10:436. doi: 10.1186/1471-2407-10-436. PMID: 20716361; PMCID: PMC2931489. 15: Hartwell D, Jones J, Loveman E, Harris P, Clegg A, Bird A. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treat Rev. 2011 May;37(3):242-9. doi: 10.1016/j.ctrv.2010.07.005. Epub 2010 Aug 14. PMID: 20709456. 16: Pirker R, Berzinec P, Brincat S, Kasan P, Ostoros G, Pesek M, Plāte S, Purkalne G, Rooneem R, Skricková J, Stanculeanu D, Timcheva C, Tzekova V, Zakotnik B, Zielinski CC, Zwitter M. Therapy of small cell lung cancer with emphasis on oral topotecan. Lung Cancer. 2010 Oct;70(1):7-13. doi: 10.1016/j.lungcan.2010.05.020. Epub 2010 Jun 23. PMID: 20576312. 17: Paton F, Paulden M, Saramago P, Manca A, Misso K, Palmer S, Eastwood A. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. Health Technol Assess. 2010 May;14 Suppl 1:55-62. doi: 10.3310/hta14Suppl1/08. PMID: 20507804. 18: Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2010 Mar;14(19):1-204. doi: 10.3310/hta14190. PMID: 20356561. 19: Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di Vagno G, Scambia G. Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol. 2010 Jun;74(3):163-74. doi: 10.1016/j.critrevonc.2009.08.001. Epub 2009 Sep 18. PMID: 19766512. 20: Sehouli J, Oskay-Ozcelik G. Current role and future aspects of topotecan in relapsed ovarian cancer. Curr Med Res Opin. 2009 Mar;25(3):639-51. doi: 10.1185/03007990802707139. PMID: 19232038.